phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer
The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of BZL101 (FDA IND# 59,521), an orally delivered aqueous extract from the herb Scutellaria barbata, in women with metastatic breast cancer (MBC). The trial was an open-label, phase 1B, multicenter, dose escalation...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2010-02, Vol.120 (1), p.111-118 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 118 |
|---|---|
| container_issue | 1 |
| container_start_page | 111 |
| container_title | Breast cancer research and treatment |
| container_volume | 120 |
| creator | Perez, Alejandra T Arun, Banu Tripathy, Debu Tagliaferri, Mary A Shaw, Heather S Kimmick, Gretchen G Cohen, Isaac Shtivelman, Emma Caygill, Katherine A Grady, Deborah Schactman, Mark Shapiro, Charles L |
| description | The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of BZL101 (FDA IND# 59,521), an orally delivered aqueous extract from the herb Scutellaria barbata, in women with metastatic breast cancer (MBC). The trial was an open-label, phase 1B, multicenter, dose escalation study. Eligible patients had histologically confirmed breast cancer and measurable stage IV disease. The standard phase 1 “3 + 3” study design was used to determine the MTD. Primary endpoints were toxicity and MTD of BZL101. Secondary outcomes included efficacy based on RECIST criteria. A total of 27 women with a median of 2 prior chemotherapy treatments for metastatic disease were treated in four different dose cohorts. Grade 3 and 4 adverse events (AEs) were uncommon. Dose-limiting toxicities included the following: grade 4 AST elevation, grade 3 diarrhea, grade 3 fatigue, and grade 3 rib pain. Fourteen patients were evaluable according to Response Evaluation Criteria in Solid Tumors. Investigator assessment classified three patients with stable disease for >120 days (21%). One patient was on BZL101 for 449 days and remains stable for 700 + days. Independent radiology review identified three patients with objective tumor regression (>0% and |
| doi_str_mv | 10.1007/s10549-009-0678-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_212475833</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1943537911</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-2d6c46497b64c1a2a55dd66fe06c8037bbc1cdabbf1d389673632ca317a51fe93</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi1ERbcLP4ALWEiV4BDw2LGdHGnFR6WVOJReuFhjx2lTZZPF9gr133dWWeiNgzX-eN53xi9jr0F8BCHspwxC120lBC1jm0o_YyvQVlVWgn3OVgKMrUwjzCk7y_leEGhF-4KdSkFCU9sVG3Z3mCOHC97NVGMOOGIZ5omXNODI555fh32J44h05h6Tx4L8_cWvDQj4wPs58R0J4lQy_zOUO76NBXOhq8B9irTlAacQ00t20uOY46tjXbObr19-Xn6vNj--XV1-3lRBWVMq2ZlAo7XWmzoAStS664zpozChEcp6HyB06H0PnWpaY5VRMqACixr62Ko1e7f47tL8ex9zcffzPk3U0kmQtdWNUgTBAoU055xi73Zp2GJ6cCDcIVu3ZOsoMnfI1mnSvDka7_02dv8Uf8Mk4PwI4CHGPtG_h_zEyRq0pvZrJhcu09N0G9PThP_r_nYR9Tg7vE1kfHMtBSgBtq21aNQjQ0yZlQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212475833</pqid></control><display><type>article</type><title>phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Perez, Alejandra T ; Arun, Banu ; Tripathy, Debu ; Tagliaferri, Mary A ; Shaw, Heather S ; Kimmick, Gretchen G ; Cohen, Isaac ; Shtivelman, Emma ; Caygill, Katherine A ; Grady, Deborah ; Schactman, Mark ; Shapiro, Charles L</creator><creatorcontrib>Perez, Alejandra T ; Arun, Banu ; Tripathy, Debu ; Tagliaferri, Mary A ; Shaw, Heather S ; Kimmick, Gretchen G ; Cohen, Isaac ; Shtivelman, Emma ; Caygill, Katherine A ; Grady, Deborah ; Schactman, Mark ; Shapiro, Charles L</creatorcontrib><description>The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of BZL101 (FDA IND# 59,521), an orally delivered aqueous extract from the herb Scutellaria barbata, in women with metastatic breast cancer (MBC). The trial was an open-label, phase 1B, multicenter, dose escalation study. Eligible patients had histologically confirmed breast cancer and measurable stage IV disease. The standard phase 1 “3 + 3” study design was used to determine the MTD. Primary endpoints were toxicity and MTD of BZL101. Secondary outcomes included efficacy based on RECIST criteria. A total of 27 women with a median of 2 prior chemotherapy treatments for metastatic disease were treated in four different dose cohorts. Grade 3 and 4 adverse events (AEs) were uncommon. Dose-limiting toxicities included the following: grade 4 AST elevation, grade 3 diarrhea, grade 3 fatigue, and grade 3 rib pain. Fourteen patients were evaluable according to Response Evaluation Criteria in Solid Tumors. Investigator assessment classified three patients with stable disease for >120 days (21%). One patient was on BZL101 for 449 days and remains stable for 700 + days. Independent radiology review identified three patients with objective tumor regression (>0% and <30%). The MTD was not reached, thus per protocol, the MTD was defined as the maximum administered dose of BZL101 40 g/day. In conclusion, oral administration of BZL101 was safe, well tolerated, and showed promising clinical evidence of anticancer activity in this heavily pretreated population of women with MBC.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-009-0678-5</identifier><identifier>PMID: 20054647</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Boston : Springer US</publisher><subject>Adult ; Aged ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Cancer research ; Cancer therapies ; Clinical Trial ; Clinical trials ; Female ; Gynecology. Andrology. Obstetrics ; Herbal medicine ; Humans ; Mammary gland diseases ; Maximum Tolerated Dose ; Medical sciences ; Medicine ; Medicine & Public Health ; Metastasis ; Middle Aged ; Oncology ; Phytotherapy - methods ; Plant Extracts - administration & dosage ; Plant Extracts - adverse effects ; Tumors</subject><ispartof>Breast cancer research and treatment, 2010-02, Vol.120 (1), p.111-118</ispartof><rights>Springer Science+Business Media, LLC. 2010</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c376t-2d6c46497b64c1a2a55dd66fe06c8037bbc1cdabbf1d389673632ca317a51fe93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-009-0678-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-009-0678-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22415558$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20054647$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perez, Alejandra T</creatorcontrib><creatorcontrib>Arun, Banu</creatorcontrib><creatorcontrib>Tripathy, Debu</creatorcontrib><creatorcontrib>Tagliaferri, Mary A</creatorcontrib><creatorcontrib>Shaw, Heather S</creatorcontrib><creatorcontrib>Kimmick, Gretchen G</creatorcontrib><creatorcontrib>Cohen, Isaac</creatorcontrib><creatorcontrib>Shtivelman, Emma</creatorcontrib><creatorcontrib>Caygill, Katherine A</creatorcontrib><creatorcontrib>Grady, Deborah</creatorcontrib><creatorcontrib>Schactman, Mark</creatorcontrib><creatorcontrib>Shapiro, Charles L</creatorcontrib><title>phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of BZL101 (FDA IND# 59,521), an orally delivered aqueous extract from the herb Scutellaria barbata, in women with metastatic breast cancer (MBC). The trial was an open-label, phase 1B, multicenter, dose escalation study. Eligible patients had histologically confirmed breast cancer and measurable stage IV disease. The standard phase 1 “3 + 3” study design was used to determine the MTD. Primary endpoints were toxicity and MTD of BZL101. Secondary outcomes included efficacy based on RECIST criteria. A total of 27 women with a median of 2 prior chemotherapy treatments for metastatic disease were treated in four different dose cohorts. Grade 3 and 4 adverse events (AEs) were uncommon. Dose-limiting toxicities included the following: grade 4 AST elevation, grade 3 diarrhea, grade 3 fatigue, and grade 3 rib pain. Fourteen patients were evaluable according to Response Evaluation Criteria in Solid Tumors. Investigator assessment classified three patients with stable disease for >120 days (21%). One patient was on BZL101 for 449 days and remains stable for 700 + days. Independent radiology review identified three patients with objective tumor regression (>0% and <30%). The MTD was not reached, thus per protocol, the MTD was defined as the maximum administered dose of BZL101 40 g/day. In conclusion, oral administration of BZL101 was safe, well tolerated, and showed promising clinical evidence of anticancer activity in this heavily pretreated population of women with MBC.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Clinical Trial</subject><subject>Clinical trials</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Herbal medicine</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Maximum Tolerated Dose</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Phytotherapy - methods</subject><subject>Plant Extracts - administration & dosage</subject><subject>Plant Extracts - adverse effects</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kE1v1DAQhi1ERbcLP4ALWEiV4BDw2LGdHGnFR6WVOJReuFhjx2lTZZPF9gr133dWWeiNgzX-eN53xi9jr0F8BCHspwxC120lBC1jm0o_YyvQVlVWgn3OVgKMrUwjzCk7y_leEGhF-4KdSkFCU9sVG3Z3mCOHC97NVGMOOGIZ5omXNODI555fh32J44h05h6Tx4L8_cWvDQj4wPs58R0J4lQy_zOUO76NBXOhq8B9irTlAacQ00t20uOY46tjXbObr19-Xn6vNj--XV1-3lRBWVMq2ZlAo7XWmzoAStS664zpozChEcp6HyB06H0PnWpaY5VRMqACixr62Ko1e7f47tL8ex9zcffzPk3U0kmQtdWNUgTBAoU055xi73Zp2GJ6cCDcIVu3ZOsoMnfI1mnSvDka7_02dv8Uf8Mk4PwI4CHGPtG_h_zEyRq0pvZrJhcu09N0G9PThP_r_nYR9Tg7vE1kfHMtBSgBtq21aNQjQ0yZlQ</recordid><startdate>20100201</startdate><enddate>20100201</enddate><creator>Perez, Alejandra T</creator><creator>Arun, Banu</creator><creator>Tripathy, Debu</creator><creator>Tagliaferri, Mary A</creator><creator>Shaw, Heather S</creator><creator>Kimmick, Gretchen G</creator><creator>Cohen, Isaac</creator><creator>Shtivelman, Emma</creator><creator>Caygill, Katherine A</creator><creator>Grady, Deborah</creator><creator>Schactman, Mark</creator><creator>Shapiro, Charles L</creator><general>Boston : Springer US</general><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20100201</creationdate><title>phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer</title><author>Perez, Alejandra T ; Arun, Banu ; Tripathy, Debu ; Tagliaferri, Mary A ; Shaw, Heather S ; Kimmick, Gretchen G ; Cohen, Isaac ; Shtivelman, Emma ; Caygill, Katherine A ; Grady, Deborah ; Schactman, Mark ; Shapiro, Charles L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-2d6c46497b64c1a2a55dd66fe06c8037bbc1cdabbf1d389673632ca317a51fe93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Clinical Trial</topic><topic>Clinical trials</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Herbal medicine</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Maximum Tolerated Dose</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Phytotherapy - methods</topic><topic>Plant Extracts - administration & dosage</topic><topic>Plant Extracts - adverse effects</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perez, Alejandra T</creatorcontrib><creatorcontrib>Arun, Banu</creatorcontrib><creatorcontrib>Tripathy, Debu</creatorcontrib><creatorcontrib>Tagliaferri, Mary A</creatorcontrib><creatorcontrib>Shaw, Heather S</creatorcontrib><creatorcontrib>Kimmick, Gretchen G</creatorcontrib><creatorcontrib>Cohen, Isaac</creatorcontrib><creatorcontrib>Shtivelman, Emma</creatorcontrib><creatorcontrib>Caygill, Katherine A</creatorcontrib><creatorcontrib>Grady, Deborah</creatorcontrib><creatorcontrib>Schactman, Mark</creatorcontrib><creatorcontrib>Shapiro, Charles L</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perez, Alejandra T</au><au>Arun, Banu</au><au>Tripathy, Debu</au><au>Tagliaferri, Mary A</au><au>Shaw, Heather S</au><au>Kimmick, Gretchen G</au><au>Cohen, Isaac</au><au>Shtivelman, Emma</au><au>Caygill, Katherine A</au><au>Grady, Deborah</au><au>Schactman, Mark</au><au>Shapiro, Charles L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2010-02-01</date><risdate>2010</risdate><volume>120</volume><issue>1</issue><spage>111</spage><epage>118</epage><pages>111-118</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of BZL101 (FDA IND# 59,521), an orally delivered aqueous extract from the herb Scutellaria barbata, in women with metastatic breast cancer (MBC). The trial was an open-label, phase 1B, multicenter, dose escalation study. Eligible patients had histologically confirmed breast cancer and measurable stage IV disease. The standard phase 1 “3 + 3” study design was used to determine the MTD. Primary endpoints were toxicity and MTD of BZL101. Secondary outcomes included efficacy based on RECIST criteria. A total of 27 women with a median of 2 prior chemotherapy treatments for metastatic disease were treated in four different dose cohorts. Grade 3 and 4 adverse events (AEs) were uncommon. Dose-limiting toxicities included the following: grade 4 AST elevation, grade 3 diarrhea, grade 3 fatigue, and grade 3 rib pain. Fourteen patients were evaluable according to Response Evaluation Criteria in Solid Tumors. Investigator assessment classified three patients with stable disease for >120 days (21%). One patient was on BZL101 for 449 days and remains stable for 700 + days. Independent radiology review identified three patients with objective tumor regression (>0% and <30%). The MTD was not reached, thus per protocol, the MTD was defined as the maximum administered dose of BZL101 40 g/day. In conclusion, oral administration of BZL101 was safe, well tolerated, and showed promising clinical evidence of anticancer activity in this heavily pretreated population of women with MBC.</abstract><cop>Boston</cop><pub>Boston : Springer US</pub><pmid>20054647</pmid><doi>10.1007/s10549-009-0678-5</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2010-02, Vol.120 (1), p.111-118 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_journals_212475833 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Biological and medical sciences Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer research Cancer therapies Clinical Trial Clinical trials Female Gynecology. Andrology. Obstetrics Herbal medicine Humans Mammary gland diseases Maximum Tolerated Dose Medical sciences Medicine Medicine & Public Health Metastasis Middle Aged Oncology Phytotherapy - methods Plant Extracts - administration & dosage Plant Extracts - adverse effects Tumors |
| title | phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T23%3A52%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=phase%201B%20dose%20escalation%20trial%20of%20Scutellaria%20barbata%20(BZL101)%20for%20patients%20with%20metastatic%20breast%20cancer&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Perez,%20Alejandra%20T&rft.date=2010-02-01&rft.volume=120&rft.issue=1&rft.spage=111&rft.epage=118&rft.pages=111-118&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-009-0678-5&rft_dat=%3Cproquest_cross%3E1943537911%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212475833&rft_id=info:pmid/20054647&rfr_iscdi=true |